Skip to content

Piper Sandler PIPR Short-term securities

Short-term securities at other companies

MetLife logo
MetLifeMET
$4.95B-10.7%
DexCom logo
DexComDXCM
$1.3B
Sachem Capital Corp. logo
Sachem Capital Corp.SACH
$795K-42.9%
Equitable Holdings logo
Equitable HoldingsEQH
$3M-91.2%
Generate Biomedicines, Inc.
 logo
Generate Biomedicines, Inc. GENB
$356.07M
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$548.88M+26.8%

Other financials

Income statement

See full
Revenue$474.4M+32.8%
Net income$65.2M+0.5%
EPS (diluted)$0.92+1.1%

Balance sheet

See full
Cash & equivalents$344.4M+173%
Total debt$112.2M-3.0%
Total equity$1.3B+10.6%
Total assets$2.1B+17.0%

Cash flow

See full
Operating cash flow-$291.7M-40.8%
CapEx$2.2M-80.7%
Free cash flow-$293.9M-34.6%

Valuation

See full
Market cap$5.53B+24.3%
Enterprise value$5.3B+19.3%
P/E19.6×-2.2×
P/S2.7×-0.1×

Profitability

See full
Net margin14%+0.8pp
FCF margin18%

Returns & leverage

See full
Return on equity22%+4.5pp
Debt / equity0.1×0.0×

Where this comes from

Reported directly by Piper Sandler in its filing.

Tagged under the XBRL concept pipr:FinancialInstrumentsOwnedMunicipalNotesatFairValue.

The official record: Piper Sandler’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Piper Sandler's short-term securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Piper Sandler's short-term securities?
Piper Sandler (PIPR) reported short-term securities of $101.59M in Q1 2026.
How has Piper Sandler's short-term securities changed year-over-year?
Piper Sandler's short-term securities increased by 137.3% year-over-year, from $42.81M to $101.59M.
What is the long-term trend for Piper Sandler's short-term securities?
Over 5 years (2020 to 2025), Piper Sandler's short-term securities has grown at a -7.3% compound annual growth rate (CAGR), from $28.59M to $19.53M.
What does short-term securities mean?
Includes short-term municipal notes held at fair value, serving as highly liquid instruments within the firm's balance sheet. These assets are primarily used for cash management and to meet short-term operational funding requirements.